ClinicalTrials.gg
CompletedNCT01558271Updated May 22, 2015Results posted

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

A Phase 3 interventional study of LY2189265 and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-22.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
16th of 54
492 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
21st of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 21st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.

Read the detailed description

Rescue therapy (defined as alternative antihyperglycemic medication use or dose modification of oral antihyperglycemic medication [OAM]) may have been initiated during the planned treatment period if the participant discontinued study drug or met prespecified thresholds for severe, persistent hyperglycemia. Efficacy data, as well as data for hypoglycemic episodes from participants who permanently discontinued study treatment but switched to another diabetes medication and remained in the study, were censored from the point of initiating new treatment onwards.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • GLP-1
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have had a diagnosis of type 2 diabetes mellitus before screening.
  • Participants who have been Oral Antihyperglycemic Medication (OAM)-naïve (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week prior to randomization.
  • Participants who are OAM naïve with a screening glycosylated () value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%.
  • Participants who have a (BMI) of 18.5 kilograms per meter squared (kg/m\^2) to 35.0 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a diagnosis of type 1 diabetes.
  • Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog.
  • Participants who have been receiving more than half of the maximum dose of sulfonylureas at screening.
  • Participants who have been currently taking insulin or TZD, or have had previous insulin or TZD treatment within 3 months before screening.
  • Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening.
  • Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
492 participants (actual)

Study arms

  • Experimental
    LY2189265

    Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.

    Drug: LY2189265

  • Placebo comparator
    Placebo/LY2189265

    Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.

    Drug: LY2189265 · Drug: Placebo

  • Active comparator
    Liraglutide

    Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.

    Drug: Liraglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \[OAM\] yes/no), baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks

    LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

    Time frame: Baseline, 52 weeks

  2. Percentage of Participants Who Achieved HbA1c <=6.5% or <7%

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\<25 or \>=25 kg/m\^2).

    Time frame: Up to 26 and 52 weeks

  3. Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks

    LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, 52 weeks

  4. Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks

    Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline SMBG as a covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

  5. Change From Baseline in Body Weight at 26 Weeks and 52 Weeks

    LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, 52 weeks

  6. Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks

    HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%S as a covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

  7. Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks

    HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%B as a covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

  8. Percentage of Participants With Hypoglycemic Episodes

    The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  9. 30-Day Rate of Hypoglycemic Episodes

    The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  10. Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks

    Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  11. Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks

    Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline pulse rate as a covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

  12. Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks

    Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline blood pressure as a covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

  13. Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks

    Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  14. Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks

    Pancreatic enzyme (lipase and total amylase) concentrations were measured.

    Time frame: Baseline, 26 weeks, 52 weeks

  15. Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks

    Time frame: Baseline, 26 weeks, 52 weeks

  16. Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks

    A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  17. Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks

    Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.

    Time frame: Baseline through 26 weeks and Baseline through 52 weeks

  18. Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks

    Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.

    Time frame: Baseline, 26 weeks, 52 weeks

07

Results

Posted Oct 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneLY2189265Placebo/LY2189265Liraglutide
Started28170141
Received at least 1 dose of study drug28070137
Completed 26 weeks27163128
Completed26359124
Not completed181117
Withdrew: Adverse event634
Withdrew: Lost to follow-up100
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject10612
Withdrew: Physician decision021

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \[OAM\] yes/no), baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
percentage of HbA1cLY2189265PlaceboLiraglutide
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks-1.43 ± 0.050.14 ± 0.10-1.33 ± 0.07
Statistical analysis
  • LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.57 · 95% CI -1.79 to -1.35
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.248 · Ls mean difference: -0.10 · 95% CI -0.27 to 0.07
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks

LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks
percentage of HbA1cLY2189265Placebo/LY2189265Liraglutide
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks-1.39 ± 0.06-1.55 ± 0.12-1.19 ± 0.08
Statistical analysis
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.040 · Ls mean difference: -0.20 · 95% CI -0.39 to -0.01
SecondaryPercentage of Participants Who Achieved HbA1c <=6.5% or <7%

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\<25 or \>=25 kg/m\^2).

Time frame:
Up to 26 and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HbA1c <=6.5% or <7%
percentage of participantsLY2189265Placebo/LY2189265Liraglutide
HbA1c <7%, 26 weeks71.45.969.1
HbA1c <=6.5%, 26 weeks50.01.549.3
HbA1c <7%, 52 weeks67.970.660.3
HbA1c <=6.5%, 52 weeks49.352.941.2
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · Cochran-Mantel-Haenszel · p = <0.001 (Treatment comparison for HbA1c \<7% at 26 weeks between LY2189265 and placebo.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
  • LY2189265 vs Liraglutide · Cochran-Mantel-Haenszel · p = 0.608 (Treatment comparison for HbA1c \<7% at 26 weeks between LY2189265 and Liraglutide.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
  • LY2189265 vs Placebo/LY2189265 · Cochran-Mantel-Haenszel · p = <0.001 (Treatment comparison for HbA1c \<=6.5% at 26 weeks between LY2189265 and placebo.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
  • LY2189265 vs Liraglutide · Cochran-Mantel-Haenszel · p = 0.844 (Treatment comparison for HbA1c \<=6.5% at 26 weeks between LY2189265 and Liraglutide.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
  • LY2189265 vs Liraglutide · Cochran-Mantel-Haenszel · p = 0.112 (Treatment comparison for HbA1c \<7% at 52 weeks between LY2189265 and Liraglutide.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
  • LY2189265 vs Liraglutide · Cochran-Mantel-Haenszel · p = 0.103 (Treatment comparison for HbA1c \<=6.5% at 52 weeks between LY2189265 and Liraglutide.)Pairwise comparison was adjusted for prestudy therapy (OAM yes/no), baseline BMI group (\<25 / \>=25 kg/m\^2), and baseline HbA1c group.
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks

LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks
milligrams per deciliter (mg/dL)LY2189265Placebo/LY2189265Liraglutide
26 weeks-39.18 ± 1.601.03 ± 3.30-39.75 ± 2.27
52 weeks-38.93 ± 1.72-40.93 ± 3.62-37.15 ± 2.47
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · Mixed Models Analysis · p = <0.001 (Treatment comparison for FBG at 26 weeks between LY2189265 and placebo.) · Ls mean difference: -40.21 · 95% CI -47.31 to -33.11
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.835 · Ls mean difference: 0.57 · 95% CI -4.82 to 5.96Treatment comparison for FBG at 26 weeks between LY2189265 and Liraglutide.
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.553 (Treatment comparison for FBG at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -1.77 · 95% CI -7.65 to 4.10
SecondaryChange From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks

Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline SMBG as a covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks
milligrams per deciliter (mg/dL)LY2189265Placebo/LY2189265Liraglutide
Pre-morning meal, 26 weeks-39.65 ± 1.55-0.15 ± 3.04-34.93 ± 2.19
2 hours post-morning meal, 26 weeks-69.64 ± 2.80-9.29 ± 5.48-61.67 ± 3.96
Pre-midday meal, 26 weeks-48.47 ± 2.053.91 ± 4.03-45.08 ± 2.91
2 hours post-midday meal, 26 weeks-67.57 ± 2.94-1.50 ± 5.77-66.71 ± 4.16
Pre-evening meal, 26 weeks-39.64 ± 2.159.25 ± 4.22-36.62 ± 3.05
2 hours post-evening meal-56.70 ± 2.830.93 ± 5.56-53.14 ± 4.01
Bedtime, 26 weeks-53.39 ± 2.814.26 ± 5.51-51.07 ± 3.94
Pre-morning meal, 52 weeks-37.46 ± 1.58-30.12 ± 3.10-33.41 ± 2.23
2 hours post-morning meal, 52 weeks-66.96 ± 2.87-65.91 ± 5.62-60.69 ± 4.06
Pre-midday meal, 52 weeks-47.03 ± 1.86-45.15 ± 3.64-46.25 ± 2.63
2 hours post-midday meal, 52 weeks-68.21 ± 2.74-58.52 ± 5.38-62.57 ± 3.88
Pre-evening meal, 52 weeks-41.04 ± 1.08-36.13 ± 3.70-32.86 ± 2.67
2 hours post-evening meal, 52 weeks-55.01 ± 2.58-55.26 ± 5.06-42.30 ± 3.65
Bedtime, 52 weeks-55.76 ± 2.39-51.19 ± 4.69-49.10 ± 3.35
SecondaryChange From Baseline in Body Weight at 26 Weeks and 52 Weeks

LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight at 26 Weeks and 52 Weeks
kilograms (kg)LY2189265Placebo/LY2189265Liraglutide
26 weeks-0.02 ± 0.14-0.63 ± 0.29-0.36 ± 0.20
52 weeks-0.17 ± 0.18-1.03 ± 0.37-0.13 ± 0.26
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · Mixed Models Analysis · p = 0.057 · Ls mean difference: 0.61 · 95% CI -0.02 to 1.23Treatment comparison for body weight at 26 weeks between LY2189265 and placebo.
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.168 (Treatment comparison for body weight at 26 weeks between LY2189265 and Liraglutide.) · Ls mean difference: 0.34 · 95% CI -0.14 to 0.82
  • LY2189265 vs Liraglutide · Mixed Models Analysis · p = 0.911 (Treatment comparison for body weight at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -0.03 · 95% CI -0.64 to 0.57
SecondaryChange From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks

HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%S as a covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks
percentage of HOMA2LY2189265Placebo/LY2189265Liraglutide
HOMA2-%S based on FI, 26 weeks (n=254, 57, 115)-4.83 ± 2.34-2.97 ± 4.83-4.82 ± 3.43
HOMA2-%S based on FCP, 26 weeks (n=275, 62, 131)-5.48 ± 1.93-6.32 ± 3.99-2.46 ± 2.75
HOMA2-%S based on FI, 52 weeks (n=260, 60, 120)-7.75 ± 2.34NA ± NA-5.26 ± 3.38
HOMA2-%S based on FCP, 52 weeks (n=275, 62, 131)-11.72 ± 1.88NA ± NA-10.68 ± 2.68
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · ANCOVA · p = 0.723 (Treatment comparison for HOMA2-%S based on fasting insulin at 26 weeks between LY2189265 and placebo.) · Ls mean difference: -1.86 · 95% CI -12.20 to 8.48
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.998 (Treatment comparison for HOMA2-%S based on fasting insulin at 26 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -0.01 · 95% CI -7.92 to 7.91
  • LY2189265 vs Placebo/LY2189265 · ANCOVA · p = 0.848 (Treatment comparison for HOMA2-%S based on fasting C-peptide at 26 weeks between LY2189265 and placebo.) · Ls mean difference: 0.83 · 95% CI -7.72 to 9.38
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.357 (Treatment comparison for HOMA2-%S based on fasting C-peptide at 26 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -3.03 · 95% CI -9.48 to 3.42
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.533 (Treatment comparison for HOMA2-%S based on fasting insulin at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -2.49 · 95% CI -10.35 to 5.36
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.747 (Treatment comparison for HOMA2-%S based on fasting C-peptide at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: -1.03 · 95% CI -7.32 to 5.25
SecondaryChange From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks

HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%B as a covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks
percentage of HOMA2LY2189265Placebo/LY2189265Liraglutide
HHOMA2-%B based on FI, 26 weeks (n=254, 57, 115)28.42 ± 1.540.08 ± 3.1425.35 ± 2.23
HOMA2-%B based on FCP, 26 weeks (n=275, 62, 131)27.77 ± 1.272.94 ± 2.6125.86 ± 1.79
HOMA2-%B based on FI, 52 weeks (n=260, 60, 120)27.81 ± 1.39NA ± NA25.89 ± 1.99
HOMA2-%B based on FCP, 52 weeks (n=275, 62, 131)29.59 ± 1.37NA ± NA28.85 ± 1.93
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · ANCOVA · p = <0.001 (Treatment comparison for HOMA2-%B based on fasting insulin at 26 weeks between LY2189265 and placebo.) · Ls mean difference: 28.35 · 95% CI 21.63 to 35.07
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.242 (Treatment comparison for HOMA2-%B based on fasting insulin at 26 weeks between LY2189265 and Liraglutide.) · Ls mean difference: 3.08 · 95% CI -2.09 to 8.24
  • LY2189265 vs Placebo/LY2189265 · ANCOVA · p = <0.001 (Treatment comparison for HOMA2-%B based on fasting C-peptide at 26 weeks between LY2189265 and placebo.) · Ls mean difference: 24.82 · 95% CI 19.25 to 30.40
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.376 (Treatment comparison for HOMA2-%B based on fasting C-peptide at 26 weeks between LY2189265 and Liraglutide.) · Ls mean difference: 1.91 · 95% CI -2.32 to 6.13
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.417 (Treatment comparison for HOMA2-%B based on fasting insulin at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: 1.91 · 95% CI -2.72 to 6.54
  • LY2189265 vs Liraglutide · ANCOVA · p = 0.753 (Treatment comparison for HOMA2-%B based on fasting C-peptide at 52 weeks between LY2189265 and Liraglutide.) · Ls mean difference: 0.73 · 95% CI -3.83 to 5.29
SecondaryPercentage of Participants With Hypoglycemic Episodes

The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemic Episodes
percentage of participantsLY2189265Placebo/LY2189265Liraglutide
26 weeks2.11.41.5
52 weeks2.92.92.9
Statistical analysis
  • LY2189265 vs Placebo/LY2189265 · Fisher Exact · p = >0.999 (Treatment comparison at 26 weeks between LY2189265 and placebo.)
  • LY2189265 vs Liraglutide · Fisher Exact · p = >0.999 (Treatment comparison at 26 weeks between LY2189265 and Liraglutide.)
  • LY2189265 vs Liraglutide · Fisher Exact · p = >0.999 (Treatment comparison at 52 weeks between LY2189265 and Liraglutide.)
Secondary30-Day Rate of Hypoglycemic Episodes

The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Mean · events per participant per 30 days
30-Day Rate of Hypoglycemic Episodes
events per participant per 30 daysLY2189265Placebo/LY2189265Liraglutide
26 weeks0.01 ± 0.040.00 ± 0.020.00 ± 0.02
52 weeks0.00 ± 0.020.01 ± 0.090.01 ± 0.04
SecondaryNumber of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks

Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks
participantsLY2189265Placebo/LY2189265Liraglutide
26 weeks000
52 weeks000
SecondaryChange From Baseline in Pulse Rate at 26 Weeks and 52 Weeks

Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline pulse rate as a covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks
beats per minute (bpm)LY2189265Placebo/LY2189265Liraglutide
26 weeks3.35 ± 0.451.49 ± 0.904.77 ± 0.64
52 weeks3.11 ± 0.424.42 ± 0.865.13 ± 0.60
SecondaryChange From Baseline in Blood Pressure at 26 Weeks and 52 Weeks

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline blood pressure as a covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · milliliters of mercury (mmHG)
Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks
milliliters of mercury (mmHG)LY2189265Placebo/LY2189265Liraglutide
SBP, 26 weeks0.62 ± 0.620.53 ± 1.25-2.10 ± 0.89
DBP, 26 weeks1.09 ± 0.390.29 ± 0.780.43 ± 0.56
SBP, 52 weeks1.32 ± 0.660.37 ± 1.37-1.86 ± 0.95
DBP, 52 weeks1.41 ± 0.411.16 ± 0.861.17 ± 0.60
SecondaryNumber of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks

Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks
participantsLY2189265Placebo/LY2189265Liraglutide
26 weeks000
52 weeks000
SecondaryChange From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks

Pancreatic enzyme (lipase and total amylase) concentrations were measured.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Median · units/liter
Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks
units/literLY2189265Placebo/LY2189265Liraglutide
Lipase, 26 weeks7.0 (1.0 to 13.0)1.0 (-6.0 to 5.0)11.0 (5.0 to 21.0)
Total Amylase, 26 weeks7.0 (2.0 to 15.0)0.0 (-6.0 to 6.0)7.0 (1.0 to 15.0)
Lipase, 52 weeks6.0 (1.0 to 12.0)6.0 (2.0 to 12.0)9.0 (3.0 to 19.0)
Total Amylase, 52 weeks7.0 (1.0 to 14.0)9.0 (3.0 to 14.0)6.0 (1.0 to 11.0)
SecondaryChange From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks
Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Median · picograms/milliliter
Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks
picograms/milliliterLY2189265Placebo/LY2189265Liraglutide
26 weeks0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
52 weeks0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryNumber of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks

A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks
participantsLY2189265Placebo/LY2189265Liraglutide
26 weeks (n=279, 68, 133)300
52 weeks (n=279, 68, 134)300
SecondaryNumber of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks

Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.

Time frame:
Baseline through 26 weeks and Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks
participantsLY2189265Placebo/LY2189265Liraglutide
26 weeks000
52 weeks000
SecondaryChange From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks

Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks
milliseconds (msec)LY2189265Placebo/LY2189265Liraglutide
QTcF, 26 weeks (n=273, 64, 128)-2.02 ± 0.70-0.96 ± 1.44-1.89 ± 1.02
QTcF, 52 weeks (n=274, 64, 128)-2.76 ± 0.68-0.80 ± 1.41-4.35 ± 1.00
PR, 26 weeks (n=269, 65, 126)2.20 ± 0.60-0.45 ± 1.222.07 ± 0.88
PR, 52 weeks (n=270, 65, 126)2.81 ± 0.822.60 ± 1.333.71 ± 1.03

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2189265—9/280 (3.2%)182/280 (65%)
Placebo/LY2189265—5/70 (7.1%)53/70 (75.7%)
Liraglutide—7/137 (5.1%)94/137 (68.6%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventLY2189265Placebo/LY2189265Liraglutide
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/521/150/24
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2281/550/113
Wound infectionInfections and infestations0/2801/700/137
Hand fractureInjury, poisoning and procedural complications0/2801/700/137
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/2801/700/137
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2801/700/137
EosinophiliaBlood and lymphatic system disorders0/2800/701/137
Hiv infectionInfections and infestations0/2800/701/137
Pneumocystis jirovecii pneumoniaInfections and infestations0/2800/701/137
Femoral neck fractureInjury, poisoning and procedural complications0/2800/701/137
Most frequent other events
Showing 10 of 283
Most frequent other events
EventLY2189265Placebo/LY2189265Liraglutide
NasopharyngitisInfections and infestations52/2807/7024/137
DiarrhoeaGastrointestinal disorders20/2806/706/137
ConstipationGastrointestinal disorders22/2804/7011/137
NauseaGastrointestinal disorders17/2802/7011/137
HypoaesthesiaNervous system disorders2/2805/701/137
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/521/150/24
CystoceleReproductive system and breast disorders0/521/150/24
RectoceleReproductive system and breast disorders0/521/150/24
Decreased appetiteMetabolism and nutrition disorders2/2802/708/137
Abdominal distensionGastrointestinal disorders12/2800/707/137

Baseline characteristics

Participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)LY2189265Placebo/LY2189265LiraglutideTotal
Mean57.15 ± 9.5757.66 ± 8.3457.91 ± 10.9357.44 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)LY2189265Placebo/LY2189265LiraglutideTotal
Female52152491
Male22855113396
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LY2189265Placebo/LY2189265LiraglutideTotal
Asian28070137487
Region of Enrollment
Region of Enrollment(participants)LY2189265Placebo/LY2189265LiraglutideTotal
Japan28070137487
08

Study locations

14 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 819-0168, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-8604, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ibaraki, 302-0118, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ishikawa, 920-8641, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 235-0045, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 862-0976, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miyagi, 980-0021, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagano, 399-0006, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 532-0003, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 160-0022, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toyama, 939-0363, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 756-0095, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yokohama, 220-0012, Japan
09

References and documents

Publications

  • Iwamoto N, Matsui A, Kazama H, Oura T. Subgroup Analysis Stratified by Baseline Pancreatic beta-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes. Diabetes Ther. 2018 Feb;9(1):383-394. doi: 10.1007/s13300-017-0346-4. Epub 2017 Dec 20. PubMed 29264713 ↗
  • Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017 Jun 12;15(1):123. doi: 10.1186/s12955-017-0696-7. PubMed 28606095 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Oct 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2012
First posted
Mar 20, 2012
Start
Mar 2012
Primary completionActual
Oct 2013
CompletionActual
May 2014
Results delay requested
Apr 25, 2014
Results first posted
Oct 30, 2014
Last update
May 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01558271
Responsible party
Sponsor
First posted
Mar 20, 2012
Start date
Mar 2012
Primary completion
Oct 2013
Completion
May 2014
Results posted
Oct 30, 2014
Last update
May 22, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion